©2022 Stanford Medicine
Phase I Compare OS in Post-CyberKnife Radiosurgery Tx in 1-3 VS 4 or More Brain Metastases
Trial ID: NCT01778764
The investigators will learn from this study if the CyberKnife radiosurgery (CK RS) treatment of patients with 1-3 versus 4 or more brain metastases results in the same overall survivals. The importance of this new knowledge will be to determine the treatment efficacy of CK RS with 1-3 versus 4 or more brain metastases. The outcome of this trial would give data to support either the continuation or modification of the CK RS treatment of patients with brain metastases.
A Comparison of Overall Survival Post-CyberKnife Radiosurgery Treatment of Patients With 1-3 Versus 4 or More Brain Metastases
1. the presence of a tumor metastasis or tumor metastases to the brain as manifested by
the neurological examination and visibility of the metastatic lesion(s) on MRI and CT
2. a Karnofsky performance status (KPS) score of greater than or equal to 60.
The exclusion criteria are the converse of the above, i.e. patients without a brain tumor
metastasis or brain tumor metastases or a KPS of less than 60.
School of Medicine
300 Pasteur Drive
Stanford, CA 94305